NasdaqGM - Nasdaq Real Time Price USD
Axsome Therapeutics, Inc. (AXSM)
At close: October 21 at 4:00 PM EDT
After hours: October 21 at 6:44 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 16 | 15 |
| Avg. Estimate | -1.41 | -1.13 | -5.71 | -2.16 |
| Low Estimate | -1.7 | -1.59 | -7.04 | -5.05 |
| High Estimate | -0.78 | -0.43 | -4.46 | 1.15 |
| Year Ago EPS | -1.32 | -2.08 | -5.27 | -5.71 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 16 | 17 | 17 |
| Avg. Estimate | 98.05M | 112.82M | 373.82M | 631.67M |
| Low Estimate | 93.9M | 103.3M | 359.37M | 469.75M |
| High Estimate | 103.5M | 124.9M | 390.5M | 753.4M |
| Year Ago Sales | -- | 71.53M | 270.6M | 373.82M |
| Sales Growth (year/est) | -- | 57.70% | 38.10% | 69.00% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1.2 | -1.17 | -1.2 | -1.33 |
| EPS Actual | -1.32 | -2.08 | -1.44 | -1.67 |
| Difference | -0.12 | -0.91 | -0.24 | -0.34 |
| Surprise % | -10.00% | -77.80% | -20.00% | -25.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.41 | -1.13 | -5.71 | -2.16 |
| 7 Days Ago | -1.34 | -1.13 | -5.56 | -2 |
| 30 Days Ago | -1.33 | -1.12 | -5.55 | -1.97 |
| 60 Days Ago | -1.31 | -1.09 | -5.48 | -1.8 |
| 90 Days Ago | -1.11 | -0.89 | -4.73 | -0.43 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 1 | -- |
| Up Last 30 Days | 1 | 2 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 4 | 3 | 4 | 3 |
Growth Estimates
| CURRENCY IN USD | AXSM | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -6.80% | -- | -- | 3.60% |
| Next Qtr. | 45.70% | -- | -- | 7.90% |
| Current Year | -8.30% | -- | -- | 2.50% |
| Next Year | 62.20% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 187.90% | -- | -- | 11.87% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | RBC Capital: Outperform to Outperform | 10/4/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/20/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/16/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/9/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/5/2024 |
Related Tickers
TGTX TG Therapeutics, Inc.
24.37
+4.55%
LXRX Lexicon Pharmaceuticals, Inc.
1.9500
-6.25%
IOVA Iovance Biotherapeutics, Inc.
9.92
-3.12%
MDGL Madrigal Pharmaceuticals, Inc.
208.89
-2.59%
VKTX Viking Therapeutics, Inc.
64.34
-2.22%
CRSP CRISPR Therapeutics AG
48.51
-0.84%
AVXL Anavex Life Sciences Corp.
5.45
-3.54%
VRNA Verona Pharma plc
34.97
+0.98%
ANVS Annovis Bio, Inc.
9.82
+6.62%
EXEL Exelixis, Inc.
28.66
-0.83%